Highlights

  • Physiomics shares declined 9.08% on 16 February 2026, followed by mixed interim results
  • Total income for H1 FY26 rose 51% to GBP 528k from GBP 354k in H1 FY25.
  • Operating loss widened to GBP 327k in H1 FY26, up from GBP 249k in H1 FY25 due to new staff onboarding.
  • Revenue increased to GBP 498k in H1 FY26 from GBP 329k in H1 FY25.
  • Shareholders’ funds decreased to GBP 393k on 31 December 2025 from GBP 418k in H1 FY25.

Physiomics PLC (LSE:PYC) shares declined during the morning session on 16 February 2026, down 9.08% to GBX 0.59, despite the stock showing an 11.51% increase over the past year. Today’s price movement followed the release of its interim results for the six months ended 31 December 2025, reporting mixed financial outcomes.

Total income reached GBP 528k in H1 FY26, up 51% from GBP 354k in the same period last year, supported in part by GBP 30k of Innovate UK grant income (H1 FY25: GBP 25k). Revenue increased to GBP 498k in H1 FY26 from GBP 329k in H1 FY25.

Operating loss widened to GBP 327k in H1 FY26, compared with GBP 249k in H1 FY25, largely due to onboarding new staff and increased use of external contractors while internal staff were trained.

Cash and cash equivalents ended the period at GBP 257k in H1 FY26 compared with GBP 269k in H1 FY25, while shareholders’ funds stood at GBP 393k in H1 FY26 down from GBP 418k reported in H1 FY25.

New Contracts and Service Line Growth Drive H1 FY26

The company reported eleven new contract wins across Modelling & Simulation and Biometrics services during H1 FY26, including projects with long-term client Numab Therapeutics.

The Biometrics service line was established during the period, with Mr Jesse Thissen appointed Head of Biometrics, securing the Company’s first four Biometrics contracts. Expansion into new therapeutic areas, including arthritis, dermatology, and irritable bowel syndrome, contributed to income growth.

Additionally, Physiomics implemented its Personalised Dosing Software on the DoseMeRx platform, expanding its partnership with DoseMe Inc., allowing clinicians access for research purposes and supporting ongoing model calibration and validation.

Client Wins and Company Outlook for FY26

Following the reporting period, Physiomics secured additional contracts, including a Modelling & Simulation project for a South Korean biopharmaceutical client, a Biometrics contract supporting a UK biotech influenza antiviral study, and a Data Usage Agreement with a leading American university to access patient datasets for its dosing software.

The Board expects total income for FY26 to meet market expectations, representing a projected 27% increase from FY25. Operating expenses are anticipated to decrease in H2 FY26 due to reduced reliance on external contractors, supporting improved profitability. Additionally, the Company projects a 24% reduction in loss after tax for FY26 compared with FY25, reflecting anticipated efficiency gains and revenue from the current pipeline of contracts.

Frequently Asked Questions (FAQs)

How did Physiomics perform financially in H1 FY26?

Total income increased 51% to GBP 528k and revenue rose to GBP 498k, while operating loss widened to GBP 327k.

What drove the operating loss increase in H1 FY26?

The rise in operating loss was mainly due to onboarding new staff and higher use of external contractors.

What is the outlook for Physiomics for FY26?

The Board expects total income to grow 27% from FY25, with reduced operating expenses in H2 FY26 and a 24% expected reduction in loss after tax.